Biotoxtech Co. Ltd
Biotoxtech Co., Ltd. engages in the safety evaluation of pharmaceuticals, foods, cosmetics, cell therapeutics, chemicals, agrochemicals, and medical equipment in South Korea. It is involved in the PK/TK, ADME, and RI analysis, as well as validation and bio analysis; efficacy evaluation and screening materials; clinical pathology and business contract of histopathology; new drug development; and b… Read more
Biotoxtech Co. Ltd (086040) - Total Liabilities
Latest total liabilities as of September 2025: ₩98.39 Billion KRW
Based on the latest financial reports, Biotoxtech Co. Ltd (086040) has total liabilities worth ₩98.39 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Biotoxtech Co. Ltd - Total Liabilities Trend (2011–2024)
This chart illustrates how Biotoxtech Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Biotoxtech Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Biotoxtech Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
MSC Co. Ltd
KQ:009780
|
Korea | ₩84.28 Billion |
|
Matrimony.Com Limited
NSE:MATRIMONY
|
India | ₹2.20 Billion |
|
MasterBeef Group Ordinary Shares
NASDAQ:MB
|
USA | $260.97 Million |
|
Focus Point Holdings Bhd
KLSE:0157
|
Malaysia | RM178.71 Million |
|
Kotra Industries Bhd
KLSE:0002
|
Malaysia | RM82.90 Million |
|
Shengli Oil & Gas Pipe Holdings Limited
F:GSG
|
Germany | €633.60 Million |
|
PBG S.A
SA:PTBL3
|
Brazil | R$3.37 Billion |
Liability Composition Analysis (2011–2024)
This chart breaks down Biotoxtech Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biotoxtech Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biotoxtech Co. Ltd (2011–2024)
The table below shows the annual total liabilities of Biotoxtech Co. Ltd from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩96.11 Billion | -2.73% |
| 2023-12-31 | ₩98.80 Billion | +21.28% |
| 2022-12-31 | ₩81.47 Billion | +64.25% |
| 2021-12-31 | ₩49.60 Billion | +64.61% |
| 2020-12-31 | ₩30.13 Billion | +0.49% |
| 2019-12-31 | ₩29.98 Billion | -5.95% |
| 2018-12-31 | ₩31.88 Billion | -3.91% |
| 2017-12-31 | ₩33.18 Billion | +41.39% |
| 2016-12-31 | ₩23.47 Billion | +7.67% |
| 2015-12-31 | ₩21.79 Billion | +3.04% |
| 2014-12-31 | ₩21.15 Billion | +2.21% |
| 2013-12-31 | ₩20.69 Billion | +10.34% |
| 2012-12-31 | ₩18.75 Billion | -16.47% |
| 2011-12-31 | ₩22.45 Billion | -- |